Roche boosts its antibody arsenal with a $489M buyout

Damian Garde Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $ 488.8 million and get its hands on some ...

Roche blueprints a $466M expansion in China

Damian Garde Roche is planning to make a major splash in China, looking to spend 450 million Swiss Francs ($ 466.2 million) to build a diagnostics operation in Suzhou. FierceBiotech ...

Roche, Celgene, BMS boast a place among orphan drug royalty

Tracy Staton These days, the orphan drug business is a good place to win laurels. Which drugmakers are in line for the most impressive crowns? FiercePharma News

Merck and Roche prep breast cancer data for promising PD-1 drugs

Emily Mullin As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer ...

Bloomberg: Roche negotiating for rest of Chugai for $10B

Eric Palmer Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, more targeted buys. Of course what is targeted ...

Roche persuades U.S. judge to toss $2M Accutane verdict

Carly Helfand Roche has emerged victorious in its quest to reverse a $ 2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne med Accutane ...

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

Damian Garde AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $ 3 billion a year at its peak, and the drugmaker is working ...

J&J, Roche, Celgene and others power new cancer-drug wave

Tracy Staton In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. ...

Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments

Eric Palmer It will allow doctors to spot patients who will benefit from those treatments. FiercePharma News

Roche snags FDA nod for ‘breakthrough’ Rituxan successor

Damian Garde Just as biosimilar competition creeps up on blockbuster Rituxan, Roche and partner Biogen Idec have won FDA approval for the cancer drug's heir, marking the first success ...

Forget a Roche merger; Novartis sell-offs could be imminent, analyst says

Tracy Staton News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in deals that could be worth $ 15 billion to $ 20 billion. And no, Roche and ...

Roche, Novartis execs discount chance of R&D collaborations

John Carroll The online chatter in Bloomberg and Reuters about potential Roche deals has been flying fast and furious recently, but there's been a streak of unfounded rumors that ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS